
    
      60 HIV-infected patients will be sequentially assigned to receive 1 of 5 doses of 141W94
      alone or 141W94 plus 1592U89. After each patient has completed 4 weeks of the assigned
      regimen (Phase A), the patient will receive Epivir and Retrovir for up to 8 months (Phase B).
      Patients originally assigned, in Phase A, to receive 141W94 and 1592U89 continue to receive
      1592U89 during this period. Upon termination of Phase B, 141W94 is added to existing regimens
      of Phase B (Phase C). Phase C will last for 12 weeks.
    
  